Mindfulness-based program to reduce cravings and addictive behavior in adults
The Feasibility and Effects of Mindfulness Based Relapse Prevention (MBRP) on Reducing Craving and Addictive Behaviour in Adults With Substance Abuse Disorders
This study is testing whether an 8-week mindfulness program can help adults with substance use disorders reduce their cravings and addictive behaviors.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 9 sites (Hong Kong and 8 other locations) |
| Trial ID | NCT04034732 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a mindfulness-based relapse prevention (MBRP) program as an adjunctive therapy for adults with substance use disorders. Participants will be randomly assigned to either the MBRP program, which lasts for 8 weeks and is led by trained instructors, or a usual care control group. Outcome measures will be assessed at multiple time points, including baseline and up to 12 months post-intervention. The study aims to gather qualitative feedback from participants to improve the MBRP program and its implementation.
Who should consider this trial
Good fit: Ideal candidates are Cantonese-speaking adults who have been diagnosed with a substance use disorder and have completed treatment within the last 6 months.
Not a fit: Patients with current or lifetime psychotic disorders, imminent suicidal risk, or dementia may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could provide individuals with effective skills to manage cravings and reduce the risk of relapse in substance use disorders.
How similar studies have performed: Previous studies have shown promise for mindfulness-based interventions in addiction treatment, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fluent in Cantonese; * Has ever fulfilled the Structured Clinical Interview for DSM-IV/DSM-5 (SCID) drug module criteria for substance use disorder diagnoses; and * Has completed outpatient or inpatient treatment for substance abuse in the previous 6 months. Exclusion Criteria: * Inability to provide valid consent; * Current or lifetime psychotic disorder assessed by the Structured Clinical interview for DSM-IV/DSM-5; * Imminent suicidal risk; or * Dementia.
Where this trial is running
Hong Kong and 8 other locations
- Department of Psychiatry, AHNH, Hospital Authority — Hong Kong, Hong Kong (Not_yet_recruiting)
- Department of Psychiatry, NDH, Hospital Authority — Hong Kong, Hong Kong (Not_yet_recruiting)
- Evergreen Lutheran Centre, Hong Kong Lutheran Social Service — Hong Kong, Hong Kong (Recruiting)
- Neo-Health Group — Hong Kong, Hong Kong (Recruiting)
- PS33 - Shamshuipo Centre, Hong Kong Christian Service — Hong Kong, Hong Kong (Recruiting)
- Rainbow Lutheran Centre, Hong Kong Lutheran Social Service — Hong Kong, Hong Kong (Recruiting)
- Sane Centre — Hong Kong, Hong Kong (Recruiting)
- The Society of Rehabilitation and Crime Prevention, Oasis — Hong Kong, Hong Kong (Recruiting)
- TWGHs CROSS Centre — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Samuel YS Wong — Jcsphpc, Cuhk
- Study coordinator: Daisy DX Zhang
- Email: zhangdxdaisy@cuhk.edu.hk
- Phone: (852) 2252-8452
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.